iiinova — where your digital self keeps evolving

2 years? I think we need a plan for a 2 week update! Should we have continuously updated recs based on when new evidence comes out? I think NCCN cancer guidelines are like this #nephjc

162

I have a hard time seeing how we progress from a smorgasbord of individually good therapies to a systematic approach as to which one(s) is (are) best for an individual patient It’s a good problem but a problem nonetheless #nephjc

261

I think it we need trials with bi-pronged approaches; it’s tough when no one company (until maybe recently) has therapies in both the immune-modulatory and general nephron preserving camps. #nephjc

121

Seems like presence/absence of diabetes belongs somewhere in this algorithm? #nephjc

040

Complement inhibitor had been published on a year before the guidelines were released! And who knows what’s going to happen at #kidneywk? Is there a plan for a v2025.2? #nephjc

020

Really important point here; what is the south Asian representation in trials v real world in IgA? #nephjc

140

Povetacicept! I’m excited to see some new IgA data from everyone at #kidneywk but ApoL1 is still my one true love #nephjc

080

Michelle Rheault, MD @rheaultm.bsky.social · 25/10/2025

Josh Waitzman—I work full-time for Vertex and part-time at BIDMC. COI: Vertex has an ongoing trial of a BAFF/APRIL inhibitor. Opinions are my own and I only know what’s public. #nephjc

270

Reposted by Josh Waitzman

If treatments are available that can help at early stages of most causes of CKD (RAASi, SGLT2i, etc), why WOULDN’T we screen? Economics? How much does saving 20 years of dialysis get you? What about human costs? www.kireports.org/article/S246...

kireports.org

Urine screening to early diagnose young individuals with CKD: a call for action

Alport syndrome is an inherited disorder of basement membranes leading to progressive chronic kidney disease, hearing loss, and ocular abnormalities in many affected patients. When the authors started...

2156

Josh Waitzman @jwaitz.bsky.social · 15/10/2025

In case folks missed this, ACGME Transplant Nephrology accreditation is now a thing! If folks are Program Directors, they may need to start the process of accreditation soon. Requirements here: www.acgme.org/globalassets...

acgme.org

002

Stoners against kidney stones?

010

Jeremy Berg @jeremymberg.bsky.social · 13/10/2025

In this house we drink liquids and support #nephjc (Maybe I should get a backpack next time) Donate at: www.nephjc.com/news/2025/9/...

1115

Reposted by Josh Waitzman

This is a powerful account from a PhD student whose fellowship was terminated by NIH because it was part of a "diversity" program without any other considerations or understanding of what the program or the students were actually doing. undark.org/2025/10/09/o... 1/2

undark.org

NIH Student Grant Cancellation Will Weaken Scientific Innovation

The termination of federal F31 diversity fellowships puts many graduate students in a bind — and U.S. science at risk.

3242124

a cartoon character from the simpsons is holding a bottle of protein

Pre #nephjc bias: Team pro protein All these studies are deeply confounded and based in the pre-kidney-preserving therapy era. Let them eat steak! (Actually, let them eat vegetable sources of protein, but beans, lentils, and soy don’t rhyme with cake)

media.tenor.com

ALT: a cartoon character from the simpsons is holding a bottle of protein

2114

Joel Topf @kidneyboy.bsky.social · 11/10/2025

Loved watching @kidneyrebel.bsky.social grand rounds at @nu-nephrology.bsky.social!! Thank you for the PKD mega blocks shout out #nephjc (1), happy to be at the right overlap in my Venn diagram (2), and trying to build toward a medical specialty in a hill (3) www.youtube.com/watch?v=RlTC...

154

Reposted by Josh Waitzman

New episode of Channel Your Enthusiasm, part 2 of 3 on metabolic acidosis. Episode with chapter art, chapters, and fully referenced www.rosebook.club/episodes/202...

1136

Reposted by Josh Waitzman

Ian L Morgan @ianlmorgan.bsky.social · 10/10/2025

My op-ed just came out discussing how NIH leadership is failing early career researchers and, importantly, how we can push back and take our future into our own hands.

the-scientist.com

NIH Leadership Is Failing Early Career Researchers

Halted training programs, funding chaos, and hiring freezes jeopardize advancement options for early career researchers.

49738

Josh Waitzman @jwaitz.bsky.social · 06/10/2025

I guess this means it’s time for me to try to understand what Tregs do… (Thanks @enirenberg.bsky.social for the great explainer!)

340

Reposted by Josh Waitzman

International Society of Glomerular Disease @isgd.bsky.social · 25/09/2025

Today is #C3GAwarenessDay! At ISGD, we stand with people living with this rare kidney disease. As a medical society for #GlomerularDisease experts, we're committed to raising awareness and moving the science forward to bring more hope and solutions to the C3G community. #C3G #ISGD

Dark Teal background with white circle in middle with yellow border. In the circle it says C3G Awareness Day. Under the circle there is a hashtag #C3GAwarenessDay, and the text Every rare kidney disease deserves to be seen.

033

Reposted by Josh Waitzman

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 24/09/2025

Excellent thread below I will also plug this talk by Paola Romagnani on podocytopathies youtu.be/bRMeqaGgA9I?... #GlomCon #NephGR

youtu.be

Personalized Therapy for Podocytopathies with Prof. Paola Romagnani

YouTube video by Ottawa Nephrology

0115

Agree 100% that maintenance dialysis pts and post transplant pts deserve better quality of evidence than we have. #nephjc

261

People’s practice habits are so hard-wired in training. Lisinopril and losartan are still the most prescribed ACEi and ARB. #nephjc

110

Right: more aldo, more combo meds, advocating for GLP1 as part of lifestyle change Wrong: 130=/=120, even stronger aldo rec, even stronger GLP1 rec so that insurance will cover it #nephjc

081

Jordy Cohen @jordybc.bsky.social · 17/09/2025

If someone figures out how to change nephrology practice, please let me know #nephjc

150

Reposted by Josh Waitzman

Yes! Slide care of Paul Whelton at this year’s #Hypertension25 #nephjc

065

If someone feels bad on multiple different agents tried serially to get them below 140 that’s a special case. I do wonder if there’s an argument to look for carotid stenosis or similar in patients like this. #nephjc

040

Yes. I worry we’ve told folks “old people can ride higher” for a long time, and it’s fighting a lot of therapeutic inertia to target a lower BPs goal to prevent dementia. #nephjc

040